Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division
Mangoceuticals (NASDAQ: MGRX) has announced the acquisition of Smokeless Technology Corp.'s intellectual property and related assets, marking its strategic entry into the oral pouch delivery market. The acquisition includes product formulations, know-how, distribution, and supplier relationships from the Canadian-based pouch innovation company.
The company plans to integrate Smokeless Tech's stimulant formulations with pharmaceutical ingredients under the MangoRx and PeachesRx brands. According to Skyquest, the U.S. nicotine pouch market reached $3.13 billion in 2024, with projections for the global oral pouch market to exceed $37.34 billion by 2032.
Additionally, MGRX has appointed Tim Corkum, former President of JUUL Labs Canada and Philip Morris International executive, to lead their pouch division. The company aims to leverage its existing distribution network, compounding pharmacy relationships, and planned Diabetinol launch to position itself as a nutraceutical platform with multi-format delivery potential.
Mangoceuticals (NASDAQ: MGRX) ha annunciato l'acquisizione della proprietà intellettuale e degli asset correlati di Smokeless Technology Corp., segnando il suo ingresso strategico nel mercato delle confezioni orali. L'acquisizione comprende formulazioni di prodotto, know-how, distribuzione e rapporti con i fornitori della società canadese specializzata nell'innovazione delle confezioni.
L'azienda prevede di integrare le formulazioni stimolanti di Smokeless Tech con ingredienti farmaceutici sotto i marchi MangoRx e PeachesRx. Secondo Skyquest, il mercato statunitense delle confezioni di nicotina ha raggiunto i 3,13 miliardi di dollari nel 2024, con proiezioni che indicano un mercato globale delle confezioni orali superiore a 37,34 miliardi di dollari entro il 2032.
Inoltre, MGRX ha nominato Tim Corkum, ex Presidente di JUUL Labs Canada e dirigente di Philip Morris International, a capo della divisione confezioni. L'azienda punta a sfruttare la propria rete di distribuzione esistente, i rapporti con le farmacie galeniche e il lancio previsto di Diabetinol per posizionarsi come piattaforma nutraceutica con un potenziale di distribuzione multi-formato.
Mangoceuticals (NASDAQ: MGRX) ha anunciado la adquisición de la propiedad intelectual y activos relacionados de Smokeless Technology Corp., marcando su entrada estratégica en el mercado de bolsitas orales. La adquisición incluye formulaciones de productos, know-how, distribución y relaciones con proveedores de la empresa canadiense especializada en innovación de bolsitas.
La compañía planea integrar las formulaciones estimulantes de Smokeless Tech con ingredientes farmacéuticos bajo las marcas MangoRx y PeachesRx. Según Skyquest, el mercado estadounidense de bolsitas de nicotina alcanzó los 3.13 mil millones de dólares en 2024, con proyecciones de que el mercado global de bolsitas orales superará los 37.34 mil millones de dólares para 2032.
Además, MGRX ha nombrado a Tim Corkum, ex presidente de JUUL Labs Canada y ejecutivo de Philip Morris International, para liderar su división de bolsitas. La empresa busca aprovechar su red de distribución existente, las relaciones con farmacias de compuestos y el lanzamiento planeado de Diabetinol para posicionarse como una plataforma nutracéutica con potencial de entrega en múltiples formatos.
Mangoceuticals (NASDAQ: MGRX)는 Smokeless Technology Corp.의 지적 재산권 및 관련 자산을 인수했다고 발표하며 구강 파우치 전달 시장에 전략적으로 진입했습니다. 이번 인수에는 캐나다 기반 파우치 혁신 회사의 제품 조제법, 노하우, 유통 및 공급업체 관계가 포함됩니다.
회사는 Smokeless Tech의 각성제 조제법을 MangoRx 및 PeachesRx 브랜드의 의약품 성분과 통합할 계획입니다. Skyquest에 따르면 미국 니코틴 파우치 시장은 2024년 31억 3천만 달러에 달했으며, 전 세계 구강 파우치 시장은 2032년까지 373억 4천만 달러를 초과할 것으로 예상됩니다.
또한 MGRX는 JUUL Labs Canada의 전 사장 겸 Philip Morris International 임원인 Tim Corkum을 파우치 부문 책임자로 임명했습니다. 회사는 기존 유통망, 조제약국 관계, 예정된 Diabetinol 출시를 활용해 다중 형식 전달 가능성을 가진 뉴트라슈티컬 플랫폼으로 자리매김할 계획입니다.
Mangoceuticals (NASDAQ : MGRX) a annoncé l'acquisition de la propriété intellectuelle et des actifs liés de Smokeless Technology Corp., marquant ainsi son entrée stratégique sur le marché des sachets oraux. L'acquisition comprend les formulations de produits, le savoir-faire, la distribution et les relations avec les fournisseurs de cette entreprise canadienne innovante dans le domaine des sachets.
L'entreprise prévoit d'intégrer les formulations stimulantes de Smokeless Tech avec des ingrédients pharmaceutiques sous les marques MangoRx et PeachesRx. Selon Skyquest, le marché américain des sachets de nicotine a atteint 3,13 milliards de dollars en 2024, avec des projections indiquant que le marché mondial des sachets oraux dépassera 37,34 milliards de dollars d'ici 2032.
De plus, MGRX a nommé Tim Corkum, ancien président de JUUL Labs Canada et cadre chez Philip Morris International, à la tête de sa division sachets. L'entreprise entend tirer parti de son réseau de distribution existant, de ses relations avec les pharmacies préparatrices et du lancement prévu de Diabetinol pour se positionner comme une plateforme nutraceutique offrant un potentiel de distribution multi-formats.
Mangoceuticals (NASDAQ: MGRX) hat die Übernahme des geistigen Eigentums und der zugehörigen Vermögenswerte von Smokeless Technology Corp. bekannt gegeben und markiert damit seinen strategischen Einstieg in den Markt für orale Beutel. Die Übernahme umfasst Produktformulierungen, Know-how, Vertrieb und Lieferantenbeziehungen des kanadischen Unternehmens für Beutelinnovationen.
Das Unternehmen plant, die stimulierenden Formulierungen von Smokeless Tech mit pharmazeutischen Inhaltsstoffen unter den Marken MangoRx und PeachesRx zu integrieren. Laut Skyquest erreichte der US-amerikanische Nikotinbeutelmarkt im Jahr 2024 einen Wert von 3,13 Milliarden US-Dollar, mit Prognosen, dass der globale Markt für orale Beutel bis 2032 über 37,34 Milliarden US-Dollar steigen wird.
Darüber hinaus hat MGRX Tim Corkum, ehemaligen Präsidenten von JUUL Labs Canada und Führungskraft bei Philip Morris International, zum Leiter der Beutelabteilung ernannt. Das Unternehmen will sein bestehendes Vertriebsnetz, Beziehungen zu Apotheken mit Rezeptur und den geplanten Diabetinol-Launch nutzen, um sich als nutraceutical Plattform mit Potenzial für Multi-Format-Lieferungen zu positionieren.
- Strategic entry into fast-growing oral pouch market worth $3.13B in 2024
- Acquisition of complete IP and formulations from Smokeless Technology Corp
- Appointment of experienced industry executive Tim Corkum from JUUL Labs/Philip Morris
- Integration potential with existing MangoRx and PeachesRx product lines
- Access to established distribution network and pharmacy relationships
- Acquisition cost and terms not disclosed
- Integration and development timeline uncertainties
- Entering competitive market dominated by established players like Zyn
Insights
MGRX enters high-growth pouch market through strategic IP acquisition, leveraging existing infrastructure with industry veteran leadership.
Mangoceuticals' acquisition of Smokeless Technology's intellectual property represents a calculated entry into the rapidly expanding oral pouch delivery market. The timing appears strategic, with industry data showing the US nicotine pouch market reached
The appointment of Tim Corkum brings critical industry expertise to MGRX's executive team. Corkum's background at Philip Morris International and JUUL Labs Canada provides valuable experience in:
- Scaling alternative delivery products
- Navigating complex regulatory landscapes
- Managing consumer adoption of novel formats
- Building distribution networks for regulated products
MGRX's dual-market strategy is particularly noteworthy - they plan to develop both non-pharmaceutical wellness pouches and integrate stimulant formulations with pharmaceutical ingredients under their established MangoRx and PeachesRx brands. This approach allows them to serve multiple consumer segments through a single delivery platform.
The company's plan to leverage existing distribution networks, pharmacy relationships, and direct-to-consumer channels creates potential operational synergies that could accelerate market entry and reduce customer acquisition costs compared to a standalone launch.
Asset-light acquisition gives MGRX entry to $37B projected market while minimizing integration risks and capital requirements.
This transaction represents an intelligent adjacent market expansion strategy through an asset-light approach. By acquiring intellectual property, formulations, and supplier relationships rather than a complete operating company, Mangoceuticals potentially minimizes integration complexity while securing the essential assets needed to enter the high-growth pouch category.
The market opportunity is substantial relative to MGRX's current scale (market cap: approximately
The strategic execution plan appears well-structured:
- Leveraging existing distribution infrastructure reduces go-to-market costs
- Utilizing established pharmacy relationships provides immediate channel access
- Employing direct-to-consumer capabilities enables rapid market testing
- Creating both pharmaceutical and non-pharmaceutical applications expands addressable market
The engagement of Tim Corkum adds considerable execution credibility given his experience scaling alternative nicotine products across markets. His leadership of "smoke-free initiatives" at Philip Morris International aligns perfectly with the pouch category opportunity.
While financial terms weren't disclosed, this type of IP acquisition typically allows companies to enter new markets with lower capital requirements than full company acquisitions or extended internal R&D cycles, potentially preserving financial flexibility for commercialization efforts.
DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ: MGRX) (“Mangoceuticals” or “MGRX”), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. (“Smokeless Tech”), a Canadian-based pouch innovation company specializing in stimulant and functional pouches.
This acquisition marks a strategic expansion into the oral pouch delivery market, which we believe is one of the fastest growing sectors in consumer wellness and alternative nicotine. Mangoceuticals intends to leverage this transaction as an opportunity to both brand additional non-pharmaceutical and nutraceutical products to be sold alongside MangoRx and PeachesRx’s existing product lines as well as an opportunity to integrate Smokeless Tech’s stimulant formulations with pharmaceutical ingredients to be sold under the MangoRx and PeachesRx brand.
We believe that pouches are revolutionizing how consumers absorb wellness ingredients—from energy and mood support to nicotine alternatives and beyond. According to a recent study conducted by Skyquest, the U.S. nicotine pouch market reached
“We expect this acquisition to unlock the next phase of growth for Mangoceuticals, as we believe to have fast-tracked a go-to-market roadmap aligned with what we expect to be one of the most disruptive categories in the market today”, said Jacob Cohen, Founder and CEO of Mangoceuticals, who continued, “For Mangoceuticals, this acquisition represents a rare opportunity to enter the high-growth nutraceutical pouch delivery space, while reaffirming the company’s mission to be an investor and developer of various health and wellness companies with executable business models and intellectual properties.”
In addition, as part of its concerted effort to unlock its next phase of growth, Mangoceuticals has added significant bench strength and professional pedigree to its management team by engaging Consumer Packaged Goods (CPG) veteran and expert, Tim Corkum. Mr. Corkum, who most recently held the position of President at JUUL Labs Canada, previously spearheaded smoke-free initiatives across multiple markets during his tenure with Philip Morris International.
Mangoceuticals intends to leverage Mr. Corkum’s seasoned expertise as an opportunity to both develop newly branded non-pharmaceutical and nutraceutical products as well as to integrate stimulant formulations with pharmaceutical ingredients intended to be sold under the MangoRx and PeachesRx brands.
With the addition of Mr. Corkum to the leadership team, we plan to seek to grow, relying on our immediate strategic synergies—leveraging Mangoceuticals’ established distribution network, compounding pharmacy relationships, and planned upcoming Diabetinol launch, using influencer campaigns and direct-to-consumer sales channels that are already in the process of being deployed. We expect this to position Mangoceuticals as a high-torque nutraceutical platform with multi-format delivery potential, and believe pouches represent the next logical expansion in a fully integrated commercial strategy.
ArcStone Securities and Investments Corp., a cross border financial services firm, acted as the exclusive financial advisor for the transaction.
About Tim Corkum
Tim Corkum brings a wealth of experience and an impressive track record of driving success in global FMCG brands and Fortune 500 companies. With a background deeply rooted in strategic leadership, Tim's expertise spans across consumer-centric strategies, B2B business plans, and high-performing team development. Tim’s extensive tenure at Philip Morris International solidified his capabilities in business development, sales strategy, and reduced risk product commercialization. Tim's broad skill set, which includes leading large teams, managing multimillion-dollar budgets, and steering complex commercial projects, positions him as a transformative leader capable of providing valuable insights and strategic direction. Most recently he has served as President of JUUL Labs Canada, where his strategic insights helped the successful launch of the company’s next generation platform. His proven ability to navigate complex regulatory environments further underscores his capability to guide organizations through intricate industry landscapes.
About Mangoceuticals, Inc.
Mangoceuticals, Inc. is focused on developing a variety of men’s and women’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management for men under the brands “MangoRx” and weight management products for women under the brand “PeachesRx”. Interested consumers can visit MangoRx’s or PeachesRx’s telemedicine platform for more information. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s and/or PeachesRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com. To learn more about PeachesRx, please visit www.PeachesRx.com.
About Smokeless Tech Corp.
Smokeless Technology Corp is a Canadian based intellectual property driven company focused on creating stimulant-based pouches for the energy, mood, and nicotine replacement markets. The company has developed a proprietary portfolio of pharmaceutical grade nutraceutical based oral-absorption formulas.
Cautionary Note Regarding Forward-Looking Statements
Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, relating to, among other things: our plans for future development, growth and expansion; statements about the ability of our trials to demonstrate safety and efficacy of our product candidates, and other positive results; the risk that initial drug results are not predictive of future results or will not be able to be replicated in clinical trials or that such drugs selected for clinical development will not be successful; challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; the Company’s reliance on third parties to conduct its clinical trials; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; risks associated with interim data; including the risk that final results could differ from interim data released; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns of purchasers of health care and other of our products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment; the investigation into, outcome of the investigation regarding, and potential lawsuits, claims and actions; the outcome of certain outstanding legal matters, claims and allegations, the requirement that the Company spend cash and management’s resources on such matters, even if the Company ultimately prevails in such matters, risks associated with certain counterparties to lawsuits having significantly greater resources than us, settlements we may choose to enter into in the future and the terms thereof, and potential regulatory reviews, inquiries or lawsuits, which are brought about by claims made in private lawsuits; the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; the ability of the Company to raise funding, the terms of such funding, and dilution caused thereby; our ability to meet the continued listing requirements of Nasdaq and maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our products which have not been, and will not be, approved by the U.S. Food and Drug Administration (“ FDA “) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“ FFDCA Act “) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; claims, lawsuits and litigation relating to our intellectual property, including allegations that our intellectual property infringes on the intellectual property of others, costs related to any such claims or lawsuits and resources required to expend in connection therewith; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions and risks associated with related party relationships and agreements; the projected size of the potential market for our technologies and products; dilution caused by offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; our dependency on third-parties to prescribe and compound our products; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel), tariffs, trade wars, and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.
More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Follow MangoRx on social media:
https://www.instagram.com/mango.rx
https://x.com/mango_rx
https://www.facebook.com/MangoRxOfficial
FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com
FAQ
What is the market size for nicotine pouches that MGRX is entering in 2024?
Who did Mangoceuticals (MGRX) appoint to lead their new pouch division?
What are the growth projections for the global oral pouch market that MGRX is targeting?
What assets did MGRX acquire from Smokeless Technology Corp?
How will MGRX integrate Smokeless Technology's products with their existing brands?
